117 related articles for article (PubMed ID: 11023195)
1. Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model.
Kubuschok B; Cochlovius C; Jung W; Schmits R; Trümper L; Hartmann F; Renner C; Pfreundschuh M
Cancer Gene Ther; 2000 Sep; 7(9):1231-40. PubMed ID: 11023195
[TBL] [Abstract][Full Text] [Related]
2. Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model.
Kubuschok B; Schmits R; Hartmann F; Cochlovius C; Breit R; König J; Pistorius G; Schilling M; Renner C; Pfreundschuh M
Hum Gene Ther; 2002 May; 13(7):815-27. PubMed ID: 11975848
[TBL] [Abstract][Full Text] [Related]
3. Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.
Kubuschok B; Pfreundschuh M; Breit R; Hartmann F; Sester M; Gärtner B; König J; Murawski N; Held G; Zwick C; Neumann F
Hum Gene Ther; 2012 Dec; 23(12):1224-36. PubMed ID: 22966960
[TBL] [Abstract][Full Text] [Related]
4. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M
Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095
[TBL] [Abstract][Full Text] [Related]
5. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
[TBL] [Abstract][Full Text] [Related]
6. Mutant ras epitopes as targets for cancer vaccines.
Abrams SI; Hand PH; Tsang KY; Schlom J
Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022
[TBL] [Abstract][Full Text] [Related]
7. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
8. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules.
Liu Y; Wang H; Zhao J; Ma J; Wei L; Wu S; Xie T; Shen F; Trojan J; Habib N; Anthony DD; Wu M; Guo Y
Cancer Gene Ther; 2000 Mar; 7(3):456-65. PubMed ID: 10766352
[TBL] [Abstract][Full Text] [Related]
10. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.
Gedde-Dahl T; Spurkland A; Fossum B; Wittinghofer A; Thorsby E; Gaudernack G
Eur J Immunol; 1994 Feb; 24(2):410-4. PubMed ID: 7507844
[TBL] [Abstract][Full Text] [Related]
11. Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse.
Schendel DJ; Frankenberger B; Jantzer P; Cayeux S; Nöbetaner E; Willimsky G; Maget B; Pohla H; Blankenstein T
Gene Ther; 2000 Dec; 7(23):2007-14. PubMed ID: 11175312
[TBL] [Abstract][Full Text] [Related]
12. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
13. Efficient foreign gene expression in Epstein-Barr virus-transformed human B-cells.
Curiel TJ; Cook DR; Bogedain C; Jilg W; Harrison GS; Cotten M; Curiel DT; Wagner E
Virology; 1994 Feb; 198(2):577-85. PubMed ID: 8291240
[TBL] [Abstract][Full Text] [Related]
14. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
15. Expression of mucin (MUC-1) from a mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells.
Kilger E; Pecher G; Schwenk A; Hammerschmidt W
J Gene Med; 1999; 1(2):84-92. PubMed ID: 10738572
[TBL] [Abstract][Full Text] [Related]
16. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
Meij P; Bloemena E; Palmen N; Brink A; Vervoort MB; Meijer CJ; Middeldorp JM
Cell Immunol; 2001 Feb; 208(1):25-33. PubMed ID: 11277616
[TBL] [Abstract][Full Text] [Related]
17. Immune response to alien histocompatibility antigens on Epstein-Barr virus transformed cells.
Mori T; Koishi T; Fujii G; Ohsawa N
Jpn J Exp Med; 1982 Jun; 52(3):125-9. PubMed ID: 6290715
[TBL] [Abstract][Full Text] [Related]
18. Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes.
Chromik J; Schnürer E; Georg Meyer R; Wehler T; Tüting T; Wölfel T; Huber C; Herr W
J Immunol Methods; 2006 Jan; 308(1-2):77-89. PubMed ID: 16336973
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene.
Tao G; Hu J; Zou H; Lin Q; Liu F; Wu Y; Sun Q
Chin Med J (Engl); 2001 Jun; 114(6):623-7. PubMed ID: 11780440
[TBL] [Abstract][Full Text] [Related]
20. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
